The kidneys operate at the interface of plasma and urine by clearing molecular waste
products while retaining valuable solutes. Genetic studies of paired plasma and urine …

Electronic health record (EHR) datasets are statistically powerful but are subject to ascertainment
bias and missingness. Using the Mass General Brigham multi-institutional EHR, we …

Background Machine learning (ML) is increasingly used in research for subtype definition
and risk prediction, particularly in cardiovascular diseases. No existing ML models are …

Metabolite levels in urine may provide insights into genetic mechanisms shaping their
related pathways. We therefore investigate the cumulative contribution of rare, exonic genetic …

Background and Purpose— Coagulation factor XI (FXI) is a novel target for antithrombotic
therapy addressed by various therapeutic modalities currently in clinical development. The …

Diastole is the sequence of physiological events that occur in the heart during ventricular
filling and principally depends on myocardial relaxation and chamber stiffness. Abnormal …

Aim In 2006, Omnitrope (by Sandoz) was the first approved biosimilar in Europe. To date, 21
biosimilars for seven different biologics are on the market. The present study compared the …

Background Polypharmacy is common among patients with CKD, but little is known about
the urinary excretion of many drugs and their metabolites among patients with CKD. Methods …

Aim Sponsors and regulators have more than 10 years of experience with the development
of biosimilars in Europe. However, the regulatory pathway is still evolving. The present article …

Cardiovascular ageing is a process that begins early in life and leads to a progressive change
in structure and decline in function due to accumulated damage across diverse cell types, …